SLCO1B3 and spindle cell hemangioma: However, pretreatment with bortezomib (50–250 nM, 2–7 h) significantly decreases OATP1B3-mediated [3H]CCK-8 accumulation in HEK293-OATP1B3 stable cell line and in human SCH (Fig 5B and 5C).